IP Library Granted Patent US 11,090,304
Granted Patent B2
US 11,090,304 · App. 16/402,538 · Granted Aug 17, 2021

KRAS G12C inhibitors and methods of using the same

Inventors: John Gordon Allen (Newbury Park, CA); Jennifer Rebecca Allen (Newbury Park, CA); Ana Elena Minatti (Los Angeles, CA); Qiufen Xue (Thousand Oaks, CA); Ryan Paul Wurz (Newbury Park, CA); Christopher M. Tegley (Daly City, CA); Alexander J. Pickrell (Westlake Village, CA); Thomas T. Nguyen (Newbury Park, CA); Vu Van Ma (Oak Park, CA); Patricia Lopez (Woodland Hills, PA); Longbin Liu (Thousand Oaks, CA); David John Kopecky (Washington, DC); Michael J. Frohn (Thousand Oaks, CA); Ning Chen (Thousand Oaks, CA); Jian Jeffrey Chen (Camarillo, CA); Aaron C. Siegmund (Ventura, CA); Albert Amegadzie (Moorpark, CA); Nuria A. Tamayo (Newbury Park, CA); Shon Booker (Sherman Oaks, CA); Clifford Goodman (Thousand Oaks, CA); Mary Walton (Burlingame, CA); Nobuko Nishimura (West Hills, CA); Youngsook Shin (Thousand Oaks, CA); Jonathan D. Low (Reseda, CA); Victor J. Cee (Thousand Oaks, CA); Anthony B. Reed (Newbury Park, CA); Hui-Ling Wang (Thousand Oaks, CA); Brian Alan Lanman (Woodland Hills, CA)
Assignee: Amgen Inc.
A61K31/517A61K31/4985A61K39/39558A61P35/00C07D403/04C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,090,304
App. No.
16/402,538
Filed
May 3, 2019
Granted
Aug 17, 2021
Kind
B2
Art Unit
1628
USPC
514/480
Abstract

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Claims (4)

1. A compound having a structure selected from:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 in the form of a pharmaceutically acceptable salt.

3. A pharmaceutical formulation comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2019
From: ALLEN, JOHN GORDON; ALLEN, JENNIFER REBECCA; MINATTI, ANA ELENA; XUE, QIUFEN; WURZ, RYAN PAUL; TEGLEY, CHRISTOPHER M.; PICKRELL, ALEXANDER J.; NGUYEN, THOMAS T.; MA, VU VAN; LOPEZ, PATRICIA; LIU, LONGBIN; KOPECKY, DAVID JOHN; FROHN, MICHAEL J.; CHEN, NING; CHEN, JIAN JEFFREY; SIEGMUND, AARON C.; AMEGADZIE, ALBERT; TAMAYO, NURIA A.; BOOKER, SHON; GOODMAN, CLIFFORD; WALTON, MARY; NISHIMURA, NOBUKO; SHIN, YOUNGSOOK; LOW, JONATHAN D.; CEE, VICTOR J.; REED, ANTHONY B.; WANG, HUI-LING; LANMAN, BRIAN ALAN
To: AMGEN INC.
Reel/Frame 050415/0568 →
Continuity (2)
Provisional Application 62667282 · May 4, 2018
Related Publication 20190343838A1 · Nov 14, 2019
Cited By (19)
US 12,252,486 US 12,280,056 US 12,291,538 US 12,297,208 US 12,391,689 US 12,391,691 US 12,398,133 US 12,415,806 US 12,421,234 US 12,440,491 US 12,466,840 US 12,479,834 US 12,582,657 US 12,583,854 US 12,630,559 US 12,643,885 US 12,673,041 US 12,692,266 US 12,702,658